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Abstract
Objectives:
Dabigatran etexilate is a new oral direct thrombin inhibitor for prophylaxis of venous thromboembolism (VTE)
in patients who have elective surgery for total hip replacement (THR) or total knee replacement (TKR). Among
the advantages of dabigatran etexilate over subcutaneous prophylaxis with Low Molecular Weight Heparin
(LMWH) are reduced resource uses for (i) teaching patients to self-inject; (ii) home-care visits for
subcutaneous administration; and (iii) absence of heparin-induced thrombocytopenia (HIT). Based on the
demonstrated non-inferiority, the aim of this study was to conduct a cost-minimization analysis of oral
dabigatran etexilate vs subcutaneous low-molecular weight heparin (LMWH) and fondaparinux from the
Dutch healthcare perspective.
Methods:
A retrospective cohort study was conducted to measure resource use associated with subcutaneous
prophylaxis. Results of this study were used in the model to elucidate specific advantages of dabigatran
etexilate, next to reduced needs for self-inject teaching and lack of Heparin-Induced Thrombocytopenia.
Drug and other resource utilization data were combined with local unit costs. Probabilistic sensitivity analysis
was performed to account for uncertainty around relevant parameters included.
Results:
Home-care visits for subcutaneous administration problems were needed in 9.9% (95% CI¼ 6.4–13.4) and
9.6% (95% CI¼ 5.8–13.4) of THR and TKR patients, respectively. Based on costs for 1000 patients treated
with dabigatran etexilate vs LMWHs, per patient cost-savings with dabigatran etexilate were estimated at
E30.68 (95% CI¼ 2.01–65.52) and E23.19 (95% CI¼ 0.69–48.48) for THR and TKR, respectively. The
probability that dabigatran etexilate would be cost-saving was estimated at 98.3% and 97.9% for THR and
TKR, respectively. These cost-savings were even higher when including fondaparinux in the analysis, with
per patient cost-savings of E69.87 (43.42–106.10) and E18.33 (1.63–41.26) for THR and TKR,
respectively. Separate calculations for dabigatran etexilate vs nadroparin and dalteparin in THR resulted
in probabilities of achieving cost-savings with dabigatran etexilate of 36.2% and 100%, respectively. For
TKR these probabilities were estimated at 54.3% and 100%, respectively.
Conclusions:
Thromboprophylaxis with dabigatran etexilate is cost-saving in patients undergoing THR and TKR from the
Dutch healthcare perspective, compared to subcutaneous LMWHs.






























































Patients undergoing major orthopedic surgery are at ele-
vated risk of venous thromboembolism (VTE), including
both deep vein thrombosis (DVT) and pulmonary embo-
lism (PE). Due to a period of immobilization, the risk of
VTE persists for up to 3 months after orthopedic surgery.
The incidence of thromboembolic complications among
patients not receiving thromboprophylaxis after orthope-
dic surgery was previously estimated at 40–60% (DVT),
2–5% (non-fatal PE) and 0.1% (fatal PE)1,2. Primary pre-
vention with thromboprophylactic treatment around
orthopedic surgery reduces the risk of non-symptomatic
and symptomatic VTE considerably1,3,4. International
guidelines recommend thromboprophylaxis for patients
undergoing total hip replacement (THR) or total knee
replacement (TKR) with low molecular weight heparins
(LMWHs), fondaparinux, or vitamin K antagonists
(VKAs)1,5,6. From national and international surveys it
seems that most orthopedic patients receive thrombopro-
phylactic therapy with LMWHs7–10. In particular, data
from an observational study showed that, of adults who
have undergone THR and TKR surgery, 65–80% receive
LMWHs in the Netherlands9,10. It is recommended in
Dutch guidelines to administer LMWHs for a period of
4–6 weeks after THR and TKR surgery6. The therapeutic
complexity related to the subcutaneous route of adminis-
tration of anticoagulants may lead to reluctance of patients
to self-administer in the home-setting following discharge
from hospital or even it is impossible for them to do so.
This may lead to inaccurate dosing, low therapy compli-
ance, and, therefore, lower effectiveness of subcutaneous
thromboprophylaxis to reduce the risk of VTE in daily
practice11–15.
Dabigatran etexilate (Pradaxa, Boehringer Ingelheim,
Ingelheim, Germany) is a novel oral direct thrombin
inhibitor for prophylaxis of VTE for adult patients who
have undergone elective THR or TKR surgery. Phase III
clinical studies—RE-NOVATE and RE-MODEL—have
demonstrated non-inferiority for dabigatran etexilate vs
enoxaparin, a low-molecular weight heparin (LMWH) in
patients who have undergone THR or TKR surgery16–18.
Oral dabigatran etexilate was found to be as effective as the
subcutaneous LMWH enoxaparin in reducing the risk of
VTE and VTE-related mortality18. Also, safety of dabiga-
tran etexilate and LMWHs was comparable with a similar
bleeding profile for both these types of agents18.
Oral anticoagulants are recognized as more patient-
friendly in daily practice. In particular, the new oral
thromboprophylactic agents like dabigatran etexilate, riv-
aroxaban, and apixapan have potential advantages over
parenteral prophylaxis with LMWHs or fondaparinux,
given the absence of possible problems with subcutaneous
administration for the former. However, drug costs for,
for example, dabigatran exceed those of the LMWHs.
Yet, downstream savings might be expected related to
the advantages of the new thromboprophylactic agents.
In the Netherlands, advantages of these oral direct throm-
bin inhibitors for VTE prophylaxis include (but may not be
limited to) reduced resource use for (i) teaching patients to
self-inject, (ii) home-care visits for parenteral administra-
tion by nurses due to self-administration problems, and
(iii) absence of heparin-induced thrombocytopenia
(HIT)19,20.
Yet, only scarce information is available on the
occurrence of problems with self-administration of
subcutaneous antithrombotics at home. In particular, on
the involvement of homecare visits by a nurse to solve
these problems, no hard data exist. Several studies indicate
that such problems occur in 7.5–44% of the
patients administering LMWHs or fondaparinux at
home9,10,12–15.
This study was designed to quantify the potential
administration problems with subcutaneous thrombopro-
phylaxis by measuring the prevalence of such problems
among patients that have undergone THR or TKR.
Furthermore, based the demonstrated non-inferiority and
data on the prevalence of administration problems, we
conducted a cost-minimization analysis of oral dabigatran
etexilate vs parenteral LMWHs and fondaparinux from the
Dutch healthcare perspective.
Methods
Patient interview on administration problems
The occurrence of administration problems with subcuta-
neous administration of thromboprophylaxis was evalu-
ated among 687 Dutch patients who had undergone
THR or TKR surgery by a retrospective telephone inter-
view. The research was conducted in two regional Dutch
hospitals (De Tjongerschans, Heerenveen; Antonius
Ziekenhuis, Sneek) and one teaching hospital (Medisch
Centrum Leeuwarden) in 2008. Approval was received
from the Medical Ethical Review Committee ‘RTPO’.
Patients who had undergone THR or TKR surgery in
2008 (February–December in Heerenveen, May and June
in Sneek, and September–December in Leeuwarden)
received an informative letter in which the research was
introduced. After oral informed consent, patients were
interviewed using a structured questionnaire. Next to
patient characteristics, several questions were asked to
measure healthcare resource use (e.g. type of surgery, hos-
pital stay, instruction for administration), potential prob-
lems related to self-administration of subcutaneous
administration in the home-setting, and patients’ prefer-
ences for subcutaneous and/or oral thromboprophylaxis.
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A cost-minimization analysis was conducted to compare
oral dabigatran etexilate with subcutaneous thrombopro-
phylaxis formulations. Dutch drug-utilization patterns and
healthcare resource data were combined with local unit
costs to calculate the healthcare cost of thromboprophy-
laxis with dabigatran etexilate, LMWH, and fondaparinux
formulations. In particular, potential advantages of dabi-
gatran etexilate over LMWHs and fondaparinux could be
quantified relating to: (i) resource use incurred giving
patients and/or relatives instructions for self-administra-
tion of LMWHs or fondaparinux; (ii) homecare for the
administration of LMWHs or fondaparinux following dis-
charge from hospital; and (iii) heparin-induced thrombo-
cytopenia (HIT)19,20.
The base-case cost-minimization analysis reflects
the comparative costs and potential savings for oral vs
subcutaneous thromboprophylaxis using a mix of
LMWHs reflecting actual use. Within the healthcare
perspective used, Dutch cost data for drugs and healthcare
resource use were derived from a previous Dutch observa-
tional study9,10, and the patient interview designed
specifically for this analysis (see above). All analyses
were conducted separately for both THR and TKR surgery
populations. All costs were expressed in 2010 values, with-
out discounting, as all costs are incurred within a maxi-
mum period of 10 weeks within the same financial
year21,22.
Scenario analysis, deterministic and probabilis-
tic sensitivity analysis
Various scenario analyses were conducted based on the
different possible comparator treatment options or combi-
nations of these comparator therapies. In the absence of
data on various aspects, in probabilistic sensitivity analysis
distributions were generally chosen to follow the symmet-
ric triangular distribution, with plausible minima and
maxima (see below and Appendix). The probability of
administration problems for both the THR and TKR anal-
yses were assumed to follow a Beta distribution23. For the
occurrence of HIT, a specific study was available, enabling
the specification of a Beta distribution with observed mean
and estimated standard error20. Next to varying all rele-
vant parameters at once (multivariate), a univariate prob-
abilistic approach was elaborated to identify the
importance of each individual parameter, separately. For
this purpose, subsequently each relevant parameter was
allowed to vary over its specified distribution, with all
other parameters kept at their respective expected values
(2000 iterations per parameter). All analyses were done in
Excel (MicroSoft), using @Risk add-in (Palisade, Athica,
NY, USA) to perform probabilistic analyses.
Dutch population data
Dutch treatment guidelines recommend extended prophy-
laxis after discharge up to 6 and 4 weeks in THR and TKR,
respectively6. Based on an average hospital length of stay
of 8 days for THR as well as for TKR9,10, total treatment
periods were assumed to be 50 and 36 days for THR and
TKR, respectively24,25. In probabilistic sensitivity analysis,
symmetric triangular distributions were used (THR: min-
imum at 2 weeks, maximum at 10 weeks; TKR: minimum
at 2 week, maximum at 6 weeks)15.
Data on inpatient days and drug-utilization from July
2005–July 2006 were available for further analysis (source:
PHARMO Utrecht, a specific report on the data is avail-
able on request). To adequately reflect the patient popu-
lation who had undergone elective THR or TKR, all
admissions for hip and knee fractures were excluded9,10.
From these data, the percentage distribution of specific
LMWHs and fondaparinux used in Dutch current practice
was estimated (enoxaparin is not routinely used in the
Netherlands). We assumed that the clinical trial results
for dabigatran etexilate vs enoxaparin are also valid vs
other types of LMWHs (and fondaparinux)26. In particu-
lar, we analyzed two options for the comparator: the
LMWH mix and the LMWH/fondaparinux mix from the
daily practice observations in the PHARMO-data (for
exact percentage distributions see below). The latter
LMWH/fondaparinux comparator for dabigatran etexilate
may be considered to most closely reflect the Dutch real-
life situation, and the LMWH mix may be considered the
preferred comparator in most guidelines.
Costing
Prior to discharge from hospital, THR and TKR patients
are instructed on self-administration of subcutaneous VTE
prophylaxis to ensure that patients use the correct injec-
tion technique, to prevent needle-stick injuries, and to
early identify patients who are unable, unwilling, or
highly reluctant to inject themselves. Costs for such an
instruction were based on an assumed 30 minutes of nurs-
ing time in the hospital, according to instruction protocols
(in probabilistic sensitivity analysis: symmetric triangular
distribution with minimum 20 and maximum 40 minutes).
Given the hourly costs22, the costs for half an hour of
instruction were estimated at E15.52 per patient.
Table 1 shows the unit costs for the different types of
home care after hospital discharge, using estimated time
investments and guideline unit prices22. We considered
two options for those patients with parenteral self-admin-
istration problems at home. In particular: (i) we conserva-
tively assumed that these patients would require standard
domiciliary care anyhow for other health reasons, and we
inserted only the extra costs for a visit by a trained nurse
(for subcutaneous administration) over a visit not
Journal of Medical Economics Volume 15, Number 5 October 2012





























































requiring a trained nurse as savings for dabigatran etexilate
(E9.95 per day; difference between standard price for dom-
icillary care (E6.24) and domiciliary care by trained nurse
(E16.19)); and (ii) we assumed a maximal approach con-
sidering that these patients would have no reason for
follow-up visits for reasons other than the administration
of thromboprophylaxis and the full E16.19 per day (stan-
dard price for domiciliary car by trained nurse) was
included as savings for patients receiving dabigatran etex-
ilate. In the threshold analysis, both the conservative and
maximal approach were elaborated. In the base case, it was
assumed that the two options occurred 50–50 in practice.
In probabilistic sensitivity analysis a symmetric triangular
distribution was used for this distribution (minimum: 25%;
maximum: 75%).
In the Netherlands, dalteparin and nadroparin are the
LMWHs that are mostly used following elective orthope-
dic surgery (Table 2). Additionally, 28.2% and 12.5% of
patients undergoing THR and TKR use fondaparinux.
Based on the Z-index (‘Taxe’ reflecting the official
Dutch pricelist), daily costs for dabigatran etexilate were
assumed at E4.41 (both 150mg and 220mg), E3.45 for
dalteparin (5000 units), E2.30 for nadroparin (3800
units), and E7.66 for fondaparinux (2.5mg)27. These
daily costs and mentioned percentages translate into cost
estimates for 50 days use after THR and 36 days use after
TKR, as shown in Table 39,10,27.
Costs related to HIT were based on an 0.8% incidence
of HIT among LMWH users in the Netherlands, as
reported by ten Berg et al.28, which is in line with data
found in international studies20,29,30. In probabilistic sen-
sitivity analysis, a Beta distribution was assumed with
parameters a and  at 14 and 1640, respectively30. Costs
for HIT were assumed to amount to E3110 in 2010 and




Six hundred and eighty-seven patients (response rate
87.4%) were interviewed. Patient characteristics are pre-
sented in Table 4. A total of 511 (74.4%) of these patients
used subcutaneous thromboprophylaxis at home, with the
remainder primarily using vitamin K antagonists. Of the
interviewed patients, 48.8% reported administration prob-
lems varying from local pain, bruises, and itches. Almost
60% of all THR and TKR patients would prefer oral over
subcutaneous thromboprophylaxis, if efficacy and safety
would be comparable. Home-care visits for subcutaneous
administration problems were required by 9.9% (95%
CI¼ 6.4–13.4) and 9.6% (95% CI¼ 5.8–13.4) of THR
Table 4. Patient characteristics, homecare needs, and average duration of
hospitalization.
Characteristics Hip replacement Knee replacement
n (%) n (%)
Number of patients 372 (100) 315 (100)
Gender
Male 114 (30.6) 109 (34.6)
Female 258 (69.4) 206 (65.4)
Age (year)
40–49 7 (1.9) 2 (0.6)
50–59 55 (14.8) 54 (17.1)
60–69 119 (32.0) 114 (36.2)
70–79 147 (39.5) 101 (32.1)
80 42 (11.3) 44 (14.0)
Unknown 2 (0.5) 0 (0)
Average (SD) 69 (9) 69 (9)
Homecare
Before surgery 29 (7.8) 22 (7.0)
After surgery 221 (59.4) 158 (50.2)
Duration hospital admission
Average number of days 8; SD¼ 6 7; SD¼ 4
n, number of patients, SD, standard deviation.
Table 1. Unit costs for different types of homecare22, based on normative
durations of visits and inclusive travel costs, difference shown for whether a
(trained) nurse is involved or not (homekeeping help only).
Type Costs per unit of time
Regular homecare E6.24 for 10 minutes
Nurse E16.19 for 15 minutes
Source: ‘OP Normtijden 2008/zorgactiviteiten packet’ 2008 and personal
communication ‘thuiszorg’ (homecare) in the Netherlands.
Table 2. Percentage distribution for LMWH used in the Netherlands9,10,

















Dabigatran etexilate 221 159
Dalteparin 173 124
Nadroparin 115 83
LMWH mix 151 104
LMWH/fondaparinux mix 217 125
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and TKR patients, respectively30. As mentioned above,
homecare visits for subcutaneous administration problems
can be sub-divided in patients that solely require homecare
for administration and patients that require homecare for
administration next to other help (Table 5).
Cost-minimization analysis
Table 6 reports the costs for separate cost components and
different comparator scenarios in the base case. For both
THR and TKR, costs for treatment with dabigatran etex-
ilate exceed costs of treatment in other comparator treat-
ment scenarios. Relevant cost offsets are estimated for all
three other components: instruction, homecare, and HIT.
In general, total costs for the different treatment scenarios
were lower for dabigatran etexilate, which means that
future dabigatran etexilate use could result in cost-savings.
Dabigatran etexilate does not appear to offer cost-savings
vs nadroparin, however the additional costs are low.
Sensitivity analysis
Table 7 shows the per-patient cost-savings for dabigatran
etexilate vs the other therapeutic strategies including
probabilistic results on 95% confidence intervals and the
probabilities of achieving cost-savings with dabigatran
etexilate. Per patient cost-savings with dabigatran etexi-
late vs the observed mix for LMWHs are estimated at
E30.68 (95% CI¼ 2.01–65.52) and E23.19 (95%
CI¼ 0.69–48.48) for THR and TKR patients, respectively.
Furthermore, the probability that dabigatran etexilate
would be cost-saving is 98.3% and 97.9% for THR and
TKR, respectively. If costs of HIT are excluded from the
analysis, these cost-savings are lower and turn in low addi-
tional costs for dabigatran etexilate for TKR patients
(E3.14; 95% CI¼ 20.92–19.17). Cost-savings are
higher when including fondaparinux alongside the
observed mix of LMWHs, with per patient cost-savings
varying between E18.33 (95% CI¼ 1.63–41.26) for
TKR patients and E69.87 (95% CI¼ 43.42–106.10) for
THR patients, if using dabigatran etexilate. The probabil-
ities of achieving cost-savings with dabigatran etexilate vs
the LMWH/fondaparinux mix strategy are close to or
even 100%.
Separate calculations for dabigatran etexilate vs nadro-
parin and dalteparin in THR result in probabilities of
achieving cost-savings with dabigatran etexilate of
36.2% and 100%, respectively. These figures are essen-
tially similar for TKR. Exclusion of costs for HIT results
in overall slightly less favorable findings for dabigatran
etexilate compared to the different LMWHs (dalteparin
and nadroparin). Yet, the probability of achieving cost-
savings reduces dramatically with dabigatan etexilate vs
nadroparin, approaching 0%.
Results presented in Figures 1 and 2 show limited var-
iation around themean estimate for dabigatran etexilate vs
the LMWH mix. In particular, the percentage requiring
homecare, occurrence of HIT, and costs related to these
aspects resulted in the largest confidence intervals for the
per-patient cost-savings. However, all variations in
Table 6. Costs for 1000 patients treated with respective medications for THR and TKR (in E).
Cost components Dabigatran
etexilate
Dalteparin Nadroparin LMWH mix LMWH/fondaparinux
mix
THR
Prophylaxis (extended) 220,500 172,500 115,000 151,110 216,624
Self-administration instruction 0 15,518 15,518 15,518 15,518
Homecare 0 58,225 58,225 58,225 58,225
HIT 0 26,324 26,324 26,324 18,901
Total excluding HIT 220,500 246,243 188,743 224,853 290,366
Total including HIT 220,500 272,567 215,067 251,177 NA
TKR
Prophylaxis (extended) 157,760 124,200 82,800 103,873 125,343
Self-administration instruction 0 15,518 15,518 15,518 15,518
Homecare 0 36,232 36,232 36,232 36,232
HIT 0 26,324 26,324 26,324 23,034
Total excluding HIT 158,760 175,950 134,550 155,623 177,093
Total including HIT 158,760 202,274 160,874 181,947 NA
NA, not appilicable (no HIT assumed for the mix including fondaparinux).








9.9 (6.4–13.4) 9.2 (5.4–12.9)
Solely for
subcutaneous administration
6.4 (3.5–9.2) 6.1 (3.0–9.2)
For subcutaneous
administration and other help
3.5 (1.4–5.7) 3.1 (0.8–5.3)
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individual parameter assumptions did not result in incre-
mental costs.
Discussion
The current analysis highlights the potential for cost-sav-
ings with dabigatran etexilate as VTE prophylaxis follow-
ing orthopedic surgery vs subcutaneous thromboprophylxis
with either LMWH or fondaparinux. The higher acquisi-
ton cost of dabigatran etexilate is generally offset by
the costs for homecare, HIT, and related healthcare
resource use associated with LMWHs. Probabilistic
sensitivity analysis resulted in high probabilities of achiev-
ing cost-savings with dabigatran etexilate. Results were
estimated to be most sensitive to the percentage of patients
experiencing administration problems, occurrence of HIT,
and to the costs related to these aspects. Results were,
Figure 1. Tornado-diagram for THR showing the mean and 95% confidence limits following from univariate probabilistic sensitivity analysis.







THR excl HIT Dalteparin E25.74 (9.64–59.59) 98.1%
Nadroparin E31.76 (59.55–0.71)* 2.7%
LMWH mix E4.35 (20.88–36.79) 59.4%
LMWH/fondaparinux mix E69.87 (43.42–106.10) 100%
THR incl HIT Dalteparin E52.07 (23.75–87.38) 100%
Nadroparin E5.43 (36.16–28.96)* 36.2%
LMWH mix E30.68 (2.01–65.52) 98.3%
LMWH/fondaparinux mix NA NA
TKR excl HIT Dalteparin E17.19 (0.43–40.02) 97.9%
Nadroparin E24.21 (43.49–1.64)* 1.9%
LMWH mix E3.14 (20.92–19.17)* 34.2%
LMWH/fondaparinux mix E18.33 (1.63–41.26) 98.7%
TKR incl HIT Dalteparin E43.51 (21.49–69.66) 100%
Nadroparin E2.11 (21.84–27.84) 54.3%
LMWH mix E23.19 (0.69–48.48) 97.9%
LMWH/fondaparinux mix NA NA
*Negative cost-savings indicate costs.
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for example, less sensitive to exact durations of treatment
and training.
In the presence of non-inferiority studies for oral dabi-
gatran etexilate, we designed a cost-minimization frame-
work to analyze the health economics of dabigatran
etexilate as compared to its subcutaneous comparators.
We note that our cost-minimization framework was lim-
ited and conservative in the sense that some potential
further benefits of the oral formulation over the subcuta-
neous administration were not included. For example,
needle-stick injuries and sharps disposal will be absent
for the oral formulation, whereas it does occur in real-life
settings with subcutaneous administrations14.
Additionally, the hospital nursing staff will need less
time for administering oral dabigatran etexilate than for
parenteral formulations. Besides, platelet monitoring for
HIT and potential differences in the occurrence of VTE
assuming poor adherence to thromboprophylaxis following
discharge from the hospital could be other potential cost
drivers for the subcutaneous LMWH or oral dabigatran as
well. Finally, we note that some other economic evalua-
tions have inserted superior point estimates of dabigatran
etexilate over LMWHs into their models, as suggested in
the clinical trials32. The presented approach has been suc-
cessful for achieving reimbursement in the Netherlands
and has been acknowledged in a quality assessment of
these type of studies in the context of evidence-based med-
icine and reimbursement in the Netherlands33,34.
We generally aimed at following a conservative
approach in our analysis, for example, excluding the risk
for HIT in the full LMWH/fondaparinux mix. Yet, in the
absence of information on discounts we applied list prices
for LMWHs and fondaparinux. In practice, discount may
be provided to hospitals and could worsen our estimated
cost-effectiveness. Notably, in addition to the advantages
modeled, an oral administration route can be expected to
result in further inpatient (as well as outpatient) cost-sav-
ings due to reduced nursing-time for administration of oral
medication, and also the absence of risk for needle-stick
injuries and sharps disposal. Furthermore, recent evidence
might support limited adherence next to limited conve-
nience with self-administration of LMWHs12,13,15,35,36.
Observational studies among THR and TKR patients
have shown that 35–40% of patients have problems
with self-administration of subcutaneous prophylaxis,
which ultimately leads to a situation where 7.5–37.5% of
patients are completely or partially non-compliant,
thereby reducing the effectiveness of VTE prophylaxis
and posing risks for DVTs12,13,15. The UK’s National
Institute for Health and Clinical Excellence (NICE) esti-
mated the risk of developing DVT following orthopedic
surgery in the absence of (effective) thromboprophylaxis
to be as high as 44% for patients having THR and 27% for
patients having TKR, highlighting the importance of com-
pliance to anti-thrombotic therapy in general36. Also, we
note that our findings from the patient interviews that
Figure 2. Tornado-diagram for TKR showing the mean and 95% confidence limits following from univariate probabilistic sensitivity analysis.
Journal of Medical Economics Volume 15, Number 5 October 2012





























































almost 60% of all THR and TKR patients would prefer oral
over subcutaneous thromboprophylaxis, if efficacy and
safety would be comparable, might still under-estimate
the real preference. In particular, coping mechanisms
with the current administration form might play a role
here. Finally, we limited our scope on those costs related
to HITs actually occurring and preventable with dabiga-
tran, whereas also just suspected HITs already generate
costs. Additionally, averted HIT in general not only pro-
vides cost savings, but also reduces (though relatively rare)
devastating complications37. For the specific Dutch set-
ting, our cost-minimization approach was relevant and
appropriate. Whether the same applies to other countries
depends on various factors inclusive of the relative costs of
the different drugs involved and the specific levels of costs
for home in individual countries. Transferability to other
countries of our results may therefore be limited.
Conclusion
We conclude that—based on our conservatively designed
cost-minimization analysis—thromboprophylaxis with
dabigatran etexilate is likely to be cost-saving in patients
undergoing THR and TKR compared to its subcutaneous
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Appendix: Parameter distributions
The distributional assumptions for all parameters included are listed below. In the absence of any information on distri-




 administration only Beta (a1¼ 17.94; a2¼ 236.06)
 administration additional to other help Beta (a1¼ 9.96; a2¼ 271.04)
Treatment duration (in days) Triang (ll¼ 22; ml¼ 50; ul¼ 78)
Specific for TKR
Percentage homecare required:
 administration only Beta (a1¼ 13.94; a2¼ 214.06)
 administration additional to other help Beta (a1¼ 6.97; a2¼ 221.03)
Treatment duration (in days) Triang (ll¼ 22; ml¼ 36; ul¼ 50)
Other
Costs of homecare (based on time in minutes):
 administration only Triang (ll¼ 7.5; ml¼ 15; ul¼ 22)
 administration additional to other help Triang (ll¼ 5; ml¼ 10; ul¼ 15)
Duration of administration instruction (in minutes) Triang (ll¼ 20; ml¼ 30; ul¼ 40)
Costs of HIT Triang (ll¼ 1555; ml¼ 3110; ul¼ 4665)
Probability of HIT Beta (a1¼ 14; a2¼ 1640)
ll, lower limit; ml, most likely value; ul, upper limit.
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